These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35840518)

  • 1. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
    Park Y; Liao J; Hoang QQ
    Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
    Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
    J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain.
    Li X; Qi Z; Ni D; Lu S; Chen L; Chen X
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.
    Dederer V; Sanz Murillo M; Karasmanis EP; Hatch KS; Chatterjee D; Preuss F; Abdul Azeez KR; Nguyen LV; Galicia C; Dreier B; Plückthun A; Versees W; Mathea S; Leschziner AE; Reck-Peterson SL; Knapp S
    J Biol Chem; 2024 Jul; 300(7):107469. PubMed ID: 38876305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
    Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ
    Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease.
    Herbst S; Lewis PA
    Biochem J; 2021 Jul; 478(14):2945-2951. PubMed ID: 34328508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization.
    Pathak P; Alexander KK; Helton LG; Kentros M; LeClair TJ; Zhang X; Ho FY; Moore TT; Hall S; Guaitoli G; Gloeckner CJ; Kortholt A; Rideout H; Kennedy EJ
    ACS Chem Neurosci; 2023 Jun; 14(11):1971-1980. PubMed ID: 37200505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Closing the structure-to-function gap for LRRK2.
    Tokars V; Chen C; Parisiadou L
    Trends Biochem Sci; 2022 Mar; 47(3):187-188. PubMed ID: 34756665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.
    Huang X; Wu C; Park Y; Long X; Hoang QQ; Liao J
    FASEB J; 2019 Apr; 33(4):4814-4823. PubMed ID: 30592623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unconventional G-protein cycle of LRRK2 and Roco proteins.
    Terheyden S; Nederveen-Schippers LM; Kortholt A
    Biochem Soc Trans; 2016 Dec; 44(6):1611-1616. PubMed ID: 27913669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L'RRK de Triomphe: a solution for LRRK2 GTPase activity?
    Nixon-Abell J; Berwick DC; Harvey K
    Biochem Soc Trans; 2016 Dec; 44(6):1625-1634. PubMed ID: 27913671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 links genetic and sporadic Parkinson's disease.
    Kluss JH; Mamais A; Cookson MR
    Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease.
    Naskar A; Roy RK; Srivastava D; Patra N
    J Phys Chem B; 2024 Jul; 128(28):6657-6669. PubMed ID: 38822803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting.
    Xiong Y; Yu J
    Trends Mol Med; 2024 Oct; 30(10):982-996. PubMed ID: 39153957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric inhibition of LRRK2, where are we now.
    Soliman A; Cankara FN; Kortholt A
    Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
    Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
    Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.